OT: Stock and Investment Talk
- Thread starter RU-05
- Start date
Because an important event is coming for both companies - FDA approval of their sickle cell anemia gene therapies. This increases the future value of their assets and very likely both stocks. Pharma and biotech have unique dynamics to how investors measure value.
Risky? Hell yeah. Possible reward? Also hell yeah. :)
Due to the high reward potential, you don't need to risk too much, so small positions and trades.
Uhhhhh.... "Inflation" rose .2%. Inflation is not "going down and down." It's not rising at a rate that it has been rising, though. So the pace of rising inflation is slowing. That's the good news.Inflation keeps going down and down:
Inflation as measured by personal spending increased in line with expectations in October, possibly giving the Federal Reserve more incentive to hold rates steady and perhaps start cutting in 2024, according to a data release Thursday.
The personal consumption expenditures price index, excluding food and energy prices, ROSE 0.2% for the month and [ROSE] 3.5% on a year-over-year basis, the Commerce Department reported. Both numbers aligned with the Dow Jones consensus.
Headline inflation was flat on the month and at a 3% rate for the 12-month period, the release also showed.
Fed's favorite gauge shows inflation rose 0.2% in October and 3.5% from a year ago, as expected
The personal consumption expenditures price index was expected to increase 0.2% in October on a monthly basis and 3.5% from a year ago.www.cnbc.com
Actually, inflation is going down. That's 100% accurate. Prices are what you are talking about. They are still going up but at a slower rate.
Also, PCE headline MoM was 0.0%.....so definitely not going up. 😃
I’m sure central banks will now start snapping up Bitcoins while they’re still cheap!
PATH is currently blowing up! Also, CLRB up 10% today. :)
- Revenue of $326 million increases 24 percent year-over-year
- ARR of $1.378 billion increases 24 percent year-over-year
- Cash flow from operations reaches $42 million and non-GAAP adjusted free cash flow reaches $44 million
NEW YORK--(BUSINESS WIRE)-- UiPath, Inc. (PATH.NaE) , a leading enterprise automation software company, today announced financial results for its third quarter fiscal 2024 ended October 31, 2023.
“I am pleased with our strong third quarter results with ARR growing 24 percent year-over-year to $1.378 billion, driven by the team’s execution and the transformational results we deliver,” said Rob Enslin, UiPath Co-Chief Executive Officer. “My conversations with customers and partners validate the strategic role enterprise automation plays in digital transformation and I am excited about the investments we continue to make in AI to further extend our market leadership.”
Daniel Dines, UiPath Co-Founder and Co-Chief Executive Officer, added, “Our unwavering commitment to understanding the needs of our customers is key to our success. In our most recent platform release, 2023.10, we delivered scores of new capabilities that seamlessly translate the potential of AI into tangible action, accelerate productivity, spark innovation, and drive business outcomes for our customers.”
Financial Outlook
For the fourth quarter fiscal 2024, UiPath (PATH.NaE) expects:
Revenue in the range of $381 million to $386 million
ARR in the range of $1.450 billion to $1.455 billion as of January 31, 2024
Non-GAAP operating income of approximately $78 million
Reconciliation of non-GAAP operating income guidance to the most directly comparable GAAP measure is not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and low visibility with respect to the charges excluded from this non-GAAP measure; in particular, the effects of stock-based compensation expense specific to equity compensation awards that are directly impacted by unpredictable fluctuations in our stock price. We expect the variability of the above charges to have a significant, and potentially unpredictable, impact on our future GAAP financial results
- Revenue of $326 million increases 24 percent year-over-year
- ARR of $1.378 billion increases 24 percent year-over-year
- Cash flow from operations reaches $42 million and non-GAAP adjusted free cash flow reaches $44 million
NEW YORK--(BUSINESS WIRE)-- UiPath, Inc. (PATH.NaE) , a leading enterprise automation software company, today announced financial results for its third quarter fiscal 2024 ended October 31, 2023.
“I am pleased with our strong third quarter results with ARR growing 24 percent year-over-year to $1.378 billion, driven by the team’s execution and the transformational results we deliver,” said Rob Enslin, UiPath Co-Chief Executive Officer. “My conversations with customers and partners validate the strategic role enterprise automation plays in digital transformation and I am excited about the investments we continue to make in AI to further extend our market leadership.”
Daniel Dines, UiPath Co-Founder and Co-Chief Executive Officer, added, “Our unwavering commitment to understanding the needs of our customers is key to our success. In our most recent platform release, 2023.10, we delivered scores of new capabilities that seamlessly translate the potential of AI into tangible action, accelerate productivity, spark innovation, and drive business outcomes for our customers.”
Financial Outlook
For the fourth quarter fiscal 2024, UiPath (PATH.NaE) expects:
Revenue in the range of $381 million to $386 million
ARR in the range of $1.450 billion to $1.455 billion as of January 31, 2024
Non-GAAP operating income of approximately $78 million
Reconciliation of non-GAAP operating income guidance to the most directly comparable GAAP measure is not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and low visibility with respect to the charges excluded from this non-GAAP measure; in particular, the effects of stock-based compensation expense specific to equity compensation awards that are directly impacted by unpredictable fluctuations in our stock price. We expect the variability of the above charges to have a significant, and potentially unpredictable, impact on our future GAAP financial results
@T2Kplus20 What's your take on (UTHR) United Therapeutics Corporation? My neighbor is a senior exec there (MD, PhD via Princeton and Duke). So I "hear" good things....
Last edited:
Activist investor Nelson Peltz launches Disney proxy fight, seeks multiple board seats
Nelson Peltz and his firm, Trian, are seeking multiple seats on Disney's board, triggering a proxy fight.
It will be interesting to see if he gets a sit. I don't think so, but more importantly, he is pushing Iger to make changes (Board seats, spending cuts, expanding theme parks, getting smarter with movies, etc.).Activist investor Nelson Peltz launches Disney proxy fight, seeks multiple board seats
Nelson Peltz and his firm, Trian, are seeking multiple seats on Disney's board, triggering a proxy fight.
I know United Therapeutics pretty well. Solid company, but they are facing a serious generic challenge and competition to one of their main products (Tyvaso for pulmonary hypertension). The stock is down about 15% YTD, so it looks like investors may be waiting for more legal clarity.
If the case goes in their favor, the stock should rally hard. But you never know about court decisions!
Important question - sounds like the Saudi's are getting upset that other OPEC nations are not adhering to production levels. As such, the may flood the market, crash the price, and force some countries to make production changes.
Any thoughts on holding XOM or CVX through something like this?
The 5 month number is even better.
kinda shocking to me just how many legit players are calling for a fed cut in march
Market shenanigans on top of geopolitical gray areas ... I exited energy ETFs late last week.
I think Iger is good but "instigators" can be helpful at times. I was happy with what he did for PG, don't think he's in it anymore. He was in GE when it was tanking and has admitted it was mistake but I think he increased his stake in recent past and has always backed Culp. GE has been on nice run, multi year highs and enjoying the ride lol. I think when aerospace/aviation sheds renewables next year is when it can takeoff further assuming the economy doesn't tank. That's always been the crown jewel and when it's flying solo with an excellent CEO the bumpy ride of the last handful of years will finally be over.
On another note saw this on PFE, a name that's come up here in the past. It's one of the first stocks I ever owned. Back down below 30 lol. Same dog it's always been for the past 20+ years with a temporary boost because of the pandemic on a vaccine they didn't develop lol. They want a piece of that obesity pie that LLY and NVO are gorging on but as per usual nope they come up short. I don't follow closely but what the hell have they done after Lipitor...not much, maybe Elliquis. They were only ever good at taking over companies and acquiring drugs not sure they even do that well anymore or have opportunities because most would be too large these days.
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
I'm monitoring, got a few energy positions that I may want to bail on. Not sure if any Saudi actions would wait until the next OPEC meeting. I assume so.
I was happy to see Iger publicly admit this:I think Iger is good but "instigators" can be helpful at times. I was happy with what he did for PG, don't think he's in it anymore. He was in GE when it was tanking and has admitted it was mistake but I think he increased his stake in recent past and has always backed Culp. GE has been on nice run, multi year highs and enjoying the ride lol. I think when aerospace/aviation sheds renewables next year is when it can takeoff further assuming the economy doesn't tank. That's always been the crown jewel and when it's flying solo with an excellent CEO the bumpy ride of the last handful of years will finally be over.
On another note saw this on PFE, a name that's come up here in the past. It's one of the first stocks I ever owned. Back down below 30 lol. Same dog it's always been for the past 20+ years with a temporary boost because of the pandemic on a vaccine they didn't develop lol. They want a piece of that obesity pie that LLY and NVO are gorging on but as per usual nope they come up short. I don't follow closely but what the hell have they done after Lipitor...not much, maybe Elliquis. They were only ever good at taking over companies and acquiring drugs not sure they even do that well anymore or have opportunities because most would be too large these days.
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Disney CEO Bob Iger says company's movies have been too focused on messaging
As for Pfizer, they have been stuck in the mud for a very long time (except for the core COVID years). Eliquis is huge, but also a copromote so they share the profit. They just haven't hit on anything innovative and market changing in a long time. An obesity drug that is an oral would have been a big deal for patients (instead of regular injections). Obviously, it didn't pan out either.
I'm always a fan of energy when the economy does slow back down, as expected, I plan on jumping in hard
I'd say keep some, lighten up and the go in hard if Saudis do that. Perhaps oil goes 68 area
I'm sitting on CVX calls right now, so I may get out and wait for the Saudi's to blow up the market. LOL! And you are definitely right, afterward would be a great time to jump back in.
Powell just confirmed two things:
1. He/Fed is happy with where real rates currently are
2. As inflation continues to decline, FFR will be cut to keep real rates stable
You can clearly see, he is way more worried about tanking the economy than battling inflation.
Good summary:
Fed to move 'carefully' on interest rates as 'soft landing' takes shape, Powell says
15x in 48 hours on those $22 calls.
Definitely a long-term position, so I will start buying PLTR tomorrow and add if/when there is a meaningful dip.
For all my talk about CRSP, I totally whiffed on it and missed the move. It started rallying sooner than expected. LOL! However, I bought into BLUE at $2.85'ish, so already up nicely.
As for CLRB, they have the money/financing in place. Their recent deal is for up to $100m pending the data release:
For small biotechs, it doesn't matter about revenue, it matters if they have a valuable asset other companies want. Their lead component is for a rare form a cancer. If the phase 3 data is positive, the asset becomes worth hundreds of millions of dollars and maybe more importantly, their phospholipid drug conjugate delivery platform becomes proven medical tech capable of developing more valuable therapies.
If their upcoming data is positive, they will be worth big money and get bought by an established company. If it isn't good, they will be out of business very quickly. Gotta love biotech!
Finally, yes, my faith in RIVN is being tested due to their cash burn. Getting close to sitting it out for a while until they get their spending in order.
With the financial situation of CLRB, no one should invest a large amount of money in that stock. Anyone who puts a lot of money are either true gamblers or there is insider trading.
Or works in the industry thus can make an educated guess. All the breadcrumbs are public to assume a positive data announcement in early January. Just review their press releases and IR materials. It's an all or nothing trade. We shall see!
Nice day for small caps! S&P 500 hits a high for 2023:
www.cnbc.com
S&P 500 rises on Friday to close at 2023 high: Live updates
The Dow Jones Industrial Average notched a 2023 high and capped off its best month in over a year.
I'm definitely starting the position at a better price then he did.
Good point. BLUE pumped again today. Already up 50%. CRSP had an interesting day. My calls crashed hard in the morning, but ended well in the green after Powell essentially claimed victory.
Today added to PANW, IGV, IBM & L.
Also bought MELI.
Todays winners - WSM & FICO
Todays losers - INTC & DELL
Also bought MELI.
Todays winners - WSM & FICO
Todays losers - INTC & DELL
S&P 500 - 277 stocks are up for the year - the rest down.Nice day for small caps! S&P 500 hits a high for 2023:
S&P 500 rises on Friday to close at 2023 high: Live updates
The Dow Jones Industrial Average notched a 2023 high and capped off its best month in over a year.
What would you have earned if you only held the top 25 of these?
I wonder what would happen if at the end of the year you do the reverse? Take the 25 worst performers in 2023 and see what happens in 2024. Would they tank more or regress to the mean (i.e., rally big time!).
Great table, thanks for posting.
